Clinical trials: Head and Neck Squamous Cell Carcinomas
Head and Neck Squamous Cell Carcinoma
PBI-MST-01(NCT04541108) Substudy TAK-02: Intratumoral Microdosing of TAK-676 in HNSCC
This is a multi-center, open-label Phase 0 substudy designed to study the localized pharmacodynamics (PD) of TAK-676 alone or in combination with Carboplatin, 5-FU, or Paclitaxel within the tumor microenvironment (TME) when…
- Trial name
- NCT06062602
- Testing
- TAK-676, Carboplatin, 5-FU
- Where
- 4 sites in United States
- Volunteers
- 15 people
- Sponsor
- Presage Biosciences
Metastatic Tumor, Advanced Solid Tumor
A Clinical Study of Anti-CD70 UCAR-T in Relapsed or Refractory Solid Tumors
This is a single-center, single-arm ，open-label ，dose escalation and dose extension study. In this study we plan to evaluate the safety and efficacy of CD70-targeting UCAR-T cells in the treatment of CD70-positive refractory or…
- Conditions
- Metastatic Tumor, Advanced Solid Tumor, Renal Cell Carcinoma, Ovarian Cancer
- Trial name
- NCT06383507
- Testing
- CHT101
- Volunteers
- 18 people
- Sponsor
- Zhejiang University
Esophageal Cancer
Docetaxel, Cisplatin, and Radiation Therapy in Treating Patients With Locally Advanced Esophageal Cancer That Cannot Be Removed By Surgery
RATIONALE: Drugs used in chemotherapy, such as docetaxel and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00238407
- Testing
- Docetaxel and Cisplatin, Radiotherapy
- Where
- 10 sites in Switzerland
- Volunteers
- 21 people
- Sponsor
- Swiss Cancer Institute
Locally Advanced Head and Neck Squamous Cell Carcinoma
Neoadjuvant Radiotherapy Combined With Toripalimab for Locally Advanced Head and Neck Squamous Cell Carcinoma
This is a phase II study. Twenty-three patients with locally advanced head and neck squamous cell carcinoma were planned to be enrolled to assess the efficacy and safety of neoadjuvant immunotherapy combined with radiotherapy.
- Trial name
- NCT05861557
- Testing
- Toripalimab, Stereotactic Body Radiation Therapy (SBRT)
- Where
- 2 sites in China
- Volunteers
- 23 people
- Sponsor
- Tianjin Medical University General Hospital
Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity, Recurrent Squamous Cell Carcinoma of the Oropharynx
Photodynamic Therapy With HPPH in Treating Patients With Squamous Cell Carcinoma of the Oral Cavity
This randomized phase II trial studies how well photodynamic therapy with HPPH works in treating patients with squamous cell carcinoma of the oral cavity.
- Conditions
- Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity, Recurrent Squamous Cell Carcinoma of the Oropharynx, Recurrent Verrucous Carcinoma of the Oral Cavity, Stage I Squamous Cell Carcinoma of the Lip and Oral Cavity
- Trial name
- NCT02119728
- Testing
- HPPH, Light Infusion Therapy™, therapeutic conventional surgery
- Where
- United States
- Sponsor
- Roswell Park Cancer Institute
Advanced Solid Tumors or Non-Hodgkin's Lymphoma (NHL)
A Phase 1/2 Trial of SRA737 in Subjects With Advanced Cancer
The purpose of this clinical study is to establish the safety profile, determine the maximum tolerated dose (MTD) and recommend a Phase 2 dose and schedule of SRA737; and to evaluate the efficacy of SRA737 in…
- Trial name
- NCT02797964
- Testing
- SRA737
- Where
- 15 sites in United Kingdom
- Volunteers
- 107 people
- Sponsor
- Sierra Oncology LLC - a GSK company
Head and Neck Cancer, Squamous Cell Carcinoma
EACH: Evaluating Avelumab in Combination With Cetuximab in Head and Neck Cancer
Head \& neck (H\&N) cancer is the eighth most common cancer in the UK. Advanced H\&N cancer which has come back after treatment or has spread to other parts of the body is incurable and the average life expectancy of these…
- Trial name
- EACH (NCT03494322)
- Testing
- Avelumab, Cetuximab
- Where
- United Kingdom
- Volunteers
- 16 people
- Sponsor
- University College, London
HNSCC
Alpha Lipoic Acid to Decrease Pain and Side Effects in Concurrent Treatment of HNSCC
This is a phase I, single-center, non-randomized, 3+3 dose-escalation study of alpha lipoic acid given during chemotherapy-radiation in HNSCC patients with non-metastatic disease.
- Trial name
- NCT04042935
- Testing
- Alpha Lipoic Acid
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- University of Colorado, Denver
Oral Cavity Squamous Cell Carcinoma
Neoadjuvant Nivolumab for Oral Cancer Combined With FDG and Anti-PD-L1 PET/CT Imaging for Response Prediction
Safety and tolerability of neoadjuvant nivolumab for locally advanced resectable oral cancer, combined with [18F]BMS-986192 / [18F]-FDG PET imaging and immunomonitoring for response prediction
- Trial name
- NeoNivo (NCT03843515)
- Testing
- Nivolumab
- Where
- Netherlands
- Volunteers
- 17 people
- Sponsor
- Amsterdam UMC, location VUmc
Clinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8
Adaptive De-intensified Radiotherapy Using Circulating Tumor DNA in HPV- Associated Oropharyngeal Cancer
This phase II trial studies how well using circulating tumor deoxyribonucleic acid (DNA) to guide lower dose radiation therapy works in treating patients with human papillomavirus infection (HPV)-associated oropharyngeal cancer.
- Conditions
- Clinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Oropharyngeal Squamous Cell Carcinoma
- Trial name
- NCT06323460
- Testing
- Biospecimen Collection, Carboplatin, Cisplatin
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- Ohio State University Comprehensive Cancer Center
Head and Neck Squamous Cell Carcinoma
SCT200 Injection in Patients With Head and Neck Squamous Cell Carcinoma
The purpose of this study is to evaluate the efficacy and safety of first-line with recombinant anti-EGFR monoclonal antibody（SCT200）and standard chemotherapy in patients with Recurrent and/or Metastatic Head and Neck Squamous…
- Trial name
- NCT03744208
- Testing
- Anti-EGFR monoclonal antibody
- Volunteers
- 30 people
- Sponsor
- Shi Yuankai
Head and Neck Cancer
Identification of Predictive Factors for the Response to Anti-Programmed Cell Death Protein 1 (PD1) Immunotherapy in Head and Neck Squamous Cell Carcinoma
This project aims to organise the sampling of blood and tumor at key points of the standard of care of patients with recurrent or metastatic squamous-cell carcinoma of the head and neck (HNSCC).
- Trial name
- IPRICE (NCT05328024)
- Testing
- Immunotherapy
- Where
- France
- Volunteers
- 60 people
- Sponsor
- Centre Paul Strauss
Advanced or Metastatic Solid Tumors
A Dose Escalation/Expansion Study of ERAS-601 in Patients With Advanced or Metastatic Solid Tumors
To evaluate the safety and tolerability of escalating doses of ERAS-601 when administered as a monotherapy and in combination with other cancer therapies in study participants with advanced or metastatic solid tumors.
- Trial name
- FLAGSHP-1 (NCT04670679)
- Testing
- ERAS-601, Cetuximab, Pembrolizumab
- Where
- 14 sites in United States, Australia
- Volunteers
- 90 people
- Sponsor
- Erasca, Inc.
Head and Neck Neoplasms
Study of NC-6004 in Combination With 5-FU and Cetuximab in Patients With Head and Neck Cancer
NC-6004 is a polymeric micelle containing cisplatin as an active moiety. The nanoparticle provides sustained release of the active moiety and utilizes the enhanced permeability and retention (EPR) effect to target release of…
- Trial name
- NCT02817113
- Testing
- NC-6004, Cetuximab, 5-FU
- Where
- 3 sites in Taiwan
- Volunteers
- 4 people
- Sponsor
- Orient Europharma Co., Ltd.
Squamous Cell Carcinoma of Head and Neck
CMP-001 in Combination With Pembrolizumab in Subjects With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
CMP-001-007 is a Phase 2 study of CMP-001 intratumoral (IT) and pembrolizumab intravenous (IV) administered to participants with head and neck squamous cell carcinoma (HNSCC) who have not been previously treated with a programmed…
- Trial name
- NCT04633278
- Testing
- CMP-001, Pembrolizumab
- Where
- 19 sites in United States
- Volunteers
- 24 people
- Sponsor
- Regeneron Pharmaceuticals
Locally Recurrent Head and Neck Squamous Cell Carcinoma, Nasopharyngeal Squamous Cell Carcinoma
Birinapant and Intensity Modulated Re-Irradiation Therapy in Treating Patients With Locally Recurrent Head and Neck Squamous Cell Carcinoma
This phase I trial studies the side effects and best dose of birinapant when given together with intensity modulated re-irradiation therapy (IMRRT) in treating patients with head and neck squamous cell carcinoma that has come…
- Conditions
- Locally Recurrent Head and Neck Squamous Cell Carcinoma, Nasopharyngeal Squamous Cell Carcinoma, Sinonasal Squamous Cell Carcinoma
- Trial name
- NCT03803774
- Testing
- Biopsy Procedure, Birinapant, Computed Tomography
- Where
- 33 sites in United States
- Volunteers
- 13 people
- Sponsor
- National Cancer Institute (NCI)
Oral Squamous Cell Carcinoma
Verification of Saliva MMP-1 as a Diagnostic Marker of Oral Cavity Cancer
The study is designed to measure salivary matrix metalloproteinase-1 (MMP-1) using the enzyme-linked immunosorbent assay (ELISA) we developed previously in patients with oral potentially malignant disorders (OPMD), oral squamous…
- Trial name
- NCT05049408
- Testing
- MMP-1 Enzyme Linked Immunosorbent assay (ELISA)
- Where
- 2 sites in Taiwan
- Volunteers
- 1,160 people, healthy volunteers welcome
- Sponsor
- S&T Biomed Co., Ltd.
Carcinoma, Squamous Cell
Randomized Multicenter Study of 5 vs 6 Weekly Fraction of RT in the Treatment of SCC of the Head and Neck
Randomized multicenter study of 5 vs 6 weekly fraction of RT in the treatment of SCC of the head and neck
- Trial name
- NCT00534950
- Testing
- 5 vs 6 weekly fraction of RT
- Where
- Saudi Arabia
- Volunteers
- 200 people
- Sponsor
- King Faisal Specialist Hospital & Research Center
Esophageal Squamous Cell Carcinoma
SIB in Upper Thoracic Esophageal Squamous Cell Carcinoma
This study was designed to predict the toxicity and efficacy of Simultaneous Integrated Boost Intensity-modulated Chemoradiotherapy in Upper Thoracic I-IVA Esophageal Squamous Cell Carcinoma.
- Trial name
- NCT04115618
- Testing
- Simultaneous integrated boost intensity-modulated chemoradiotherapy
- Where
- China
- Volunteers
- 65 people
- Sponsor
- Fudan University
Advanced Solid Tumors, Lymphoma
FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid Tumors
FT500 is an off-the-shelf, iPSC-derived NK cell product that can bridge innate and adaptive immunity, and has the potential to overcome multiple mechanisms of immune checkpoint inhibitor (ICI) resistance.
- Conditions
- Advanced Solid Tumors, Lymphoma, Gastric Cancer, Colorectal Cancer
- Trial name
- NCT03841110
- Testing
- FT500, Nivolumab, Pembrolizumab
- Where
- 4 sites in United States
- Volunteers
- 37 people
- Sponsor
- Fate Therapeutics
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.